Sugi Predict

Sugi Predict / Targets / HDAC4

HDAC4

Histone deacetylase 4 · P56524 · HDAC4 on Sugi Atlas →

452,328 patent compounds predicted against HDAC4, 277,908 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL28250 SCHEMBL28250 0.57 14/20
SCHEMBL29476 SCHEMBL29476 0.57 14/20
SCHEMBL31064 SCHEMBL31064 0.57 14/20
SCHEMBL30259 SCHEMBL30259 0.57 14/20
SCHEMBL28328 SCHEMBL28328 0.61 13/20
SCHEMBL28329 SCHEMBL28329 0.61 13/20
SCHEMBL28330 SCHEMBL28330 0.61 13/20
SCHEMBL29695 SCHEMBL29695 0.61 13/20
SCHEMBL30199 SCHEMBL30199 0.61 13/20
Vorinostat Vorinostat (SCHEMBL9018) 1.00 12/20
Iodipamide Iodipamide (SCHEMBL37678) 0.41 12/20
SCHEMBL21138 SCHEMBL21138 0.55 11/20
SCHEMBL21139 SCHEMBL21139 0.55 11/20
SCHEMBL21140 SCHEMBL21140 0.55 11/20
SCHEMBL30622 SCHEMBL30622 0.55 11/20
Trichostatin Trichostatin (SCHEMBL19886) 1.00 10/20
SCHEMBL34229 SCHEMBL34229 0.51 10/20
SCHEMBL19539 SCHEMBL19539 0.48 10/20
SCHEMBL28840 SCHEMBL28840 0.61 9/20
SCHEMBL28841 SCHEMBL28841 0.61 9/20

Clinical trials — most relevant to HDAC4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas PHASE2ACTIVE_NOT_RECRUITING
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma PHASE1UNKNOWN
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
SHP-141C in Plaque Type Psoriasis PHASE1COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies PHASE1COMPLETED
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
Adoptive Transfer of Haploidentical NK Cells and N-803 PHASE1COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency nanCOMPLETED
Imaging Histone Deacetylase in the Heart nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HDAC4 binder may also engage these)

ProteinNameSimilarity
Q99P99 — 1.000 Q99P99 →
P83038 — 1.000 P83038 →
HDAC5 Histone deacetylase 5 1.000 landscape →
Q5R902 — 0.998 Q5R902 →
Q6NZM9 — 0.997 Q6NZM9 →
Q80ZH1 — 0.997 Q80ZH1 →
HDAC9 Histone deacetylase 9 0.996 landscape →
Q9Z2V6 — 0.995 Q9Z2V6 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.994 landscape →
Q9H334 — 0.993 Q9H334 →
Q58NQ4 — 0.993 Q58NQ4 →
Q6NSM8 — 0.992 Q6NSM8 →
Q9WVB2 — 0.992 Q9WVB2 →
P23899 — 0.992 P23899 →
O17323 — 0.991 O17323 →
Q9H329 — 0.991 Q9H329 →
Q62431 — 0.991 Q62431 →
Q8TBC3 — 0.990 Q8TBC3 →
Q80TZ9 — 0.990 Q80TZ9 →
Q812B1 — 0.990 Q812B1 →
Q5RER5 — 0.990 Q5RER5 →
Q2EJA0 — 0.990 Q2EJA0 →
Q63955 — 0.990 Q63955 →
P35680 — 0.990 P35680 →
P0CF24 — 0.990 P0CF24 →
Q9QZB6 — 0.990 Q9QZB6 →
Q498D1 — 0.990 Q498D1 →
Q03365 — 0.990 Q03365 →
A3KMV1 — 0.990 A3KMV1 →
P58462 — 0.990 P58462 →